195 related articles for article (PubMed ID: 6931871)
41. The use of gemfibrozil in the treatment of primary hyperlipoproteinaemia. Preliminary report.
Honorato J; Masso RM; Purroy A
Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):78-9. PubMed ID: 798200
[No Abstract] [Full Text] [Related]
42. A long-term trial of gemfibrozil in the treatment of hyperlipidaemias.
Eisalo A; Manninen V
Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):49-52. PubMed ID: 798198
[No Abstract] [Full Text] [Related]
43. [Effect of lipanthyl on parameters of lipid metabolism in patients with primary hyperlipoproteinemia].
Sznajd J; Magdoń M; Idzior B; Konarska R; Malczewska M; Czarnecka H
Przegl Lek; 1984; 41(2):217-21. PubMed ID: 6377392
[No Abstract] [Full Text] [Related]
44. Gemfibrozil therapy in primary hypertriglyceridemia associated with coronary heart disease. Effects on metabolism of low-density lipoproteins.
Vega GL; Grundy SM
JAMA; 1985 Apr; 253(16):2398-403. PubMed ID: 3856692
[TBL] [Abstract][Full Text] [Related]
45. Plasma prekallikrein, kallikrein inhibitors, kininogen and lipids during gemfibrozil treatment in type II dyslipidaemia.
Torstila I; Kaukola S; Manninen V; Virtamo J; Mälkönen M
Acta Med Scand Suppl; 1982; 668():123-9. PubMed ID: 6188330
[TBL] [Abstract][Full Text] [Related]
46. [Tolerability and side-effects of bis-(hydroxy-2-ethylthio)-1,10-decane (BS 530) as compared with clofibrate in the therapy of hyperlipemia].
Colombo L; Monarca A; Goldberg D; Zanetta R
Clin Ter; 1979 Oct; 91(2):155-71. PubMed ID: 540479
[No Abstract] [Full Text] [Related]
47. Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
Hutt V; Wechsler JG; Klör HU; Ditschuneit H
Artery; 1980; 8(2):113-9. PubMed ID: 7458676
[TBL] [Abstract][Full Text] [Related]
48. Pirifibrate in the treatment of hyperlipoproteinemia: types IIa, IIb, and IV.
Clin Ther; ; . PubMed ID: 7273061
[TBL] [Abstract][Full Text] [Related]
49.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
50.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
51.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
52.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
53.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
54.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
55.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
